Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark Uhlik"'
Autor:
Nandita Bose, Anissa S.H. Chan, Nadine Ottoson, Adria Jonas, Keith Gordon, Mark Uhlik, Xiaohong Qui, Jeremy R. Graff
Publikováno v:
Cancer Immunology Research. 8:A01-A01
Imprime PGG (Imprime), an intravenously administered, soluble, yeast β-1,3/1,6 glucan, is currently in clinical development with tumor-targeting, antiangiogenic and checkpoint inhibitor antibodies. The fundamental mechanistic rationale for these dif
Autor:
Jeremy R. Graff, Takashi Kangas, Ross B. Fulton, Yumi Yokoyama, Ben J. Harrison, Mark Uhlik, Keith B. Gorden, Steven M. Leonardo, Kathryn A. Fraser, Nandita Bose
Publikováno v:
Cancer Research. 78:3767-3767
Cancer therapy has been reshaped by checkpoint inhibitors (CPIs), making it possible for durable responses against cancers with traditionally low cure rates. Current efforts are focused on combination therapies in the hopes of evading resistance to C
Autor:
Richard D. Huhn, Mable Ma, Michael Chisamore, Richard Walsh, Steven J. O'Day, Nandita Bose, Jeremy R. Graff, Steven M. Leonardo, Bruno Osterwalder, Michele Gargano, Paulette Mattson, Mark Uhlik, Radha Prathikanti, Ben J. Harrison, Jamie Lowe, Katie Ertelt, Xiaohong Qiu, Nadine Ottoson
Publikováno v:
Molecular Cancer Therapeutics. 17:LB-A31
Imprime PGG (Imprime) is a novel immunotherapeutic that acts as a non-self danger signal to activate the innate immune system and coordinate an adaptive immune system response. In multiple preclinical tumor models, Imprime significantly enhances anti